Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.

Wang PS, Ganz DA, Benner JS, Glynn RJ, Avorn J.

J Ment Health Policy Econ. 2004 Jun;7(2):77-85.

PMID:
15208468
2.

Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model.

Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, Wang PS.

J Clin Psychopharmacol. 2005 Oct;25(5):427-34.

PMID:
16160617
3.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

4.

Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.

Essock SM, Frisman LK, Covell NH, Hargreaves WA.

Arch Gen Psychiatry. 2000 Oct;57(10):987-94.

PMID:
11015817
5.

Cost-effectiveness of clozapine monitoring after the first 6 months.

Zhang M, Owen RR, Pope SK, Smith GR.

Arch Gen Psychiatry. 1996 Oct;53(10):954-8.

PMID:
8857873
7.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
8.

[Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].

Geronimi-Ferret D, Lesay M, Barges-Bertocchio MH, Cornet-Bonnefont M, Robert H.

Encephale. 1997 Sep;23 Spec No 4:24-31. French.

PMID:
9417402
9.

Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.

Oh PI, Iskedjian M, Addis A, Lanctôt K, Einarson TR.

Can J Clin Pharmacol. 2001 Winter;8(4):199-206.

PMID:
11743592
10.

[Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].

Bret P, Jolivel C, Bret MC, Veylit S, Martin C, Garcia P.

Encephale. 1998 Jul-Aug;24(4):365-77. French.

PMID:
9809242
11.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

12.

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D.

Arch Gen Psychiatry. 1999 Jun;56(6):565-72.

PMID:
10359474
13.

Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies.

Revicki DA.

J Clin Psychiatry. 1999;60 Suppl 1:7-11; discussion 28-30. Review.

14.

Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.

Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG.

J Urol. 2009 May;181(5):2181-6. doi: 10.1016/j.juro.2009.01.037. Epub 2009 Mar 17.

PMID:
19296983
15.

Generic replacement of clozapine: a simple decision model from a Canadian perspective.

Layton S, Barbeau M.

Curr Med Res Opin. 2004 Apr;20(4):453-9.

PMID:
15119982
16.

Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.

Ginsberg G, Shani S, Lev B.

Pharmacoeconomics. 1998 Feb;13(2):231-41.

PMID:
10178649
17.

Outcome in schizophrenia: beyond symptom reduction.

Meltzer HY.

J Clin Psychiatry. 1999;60 Suppl 3:3-7; discussion 8. Review.

18.

Cost-effectiveness of group psychotherapy for depression in Uganda.

Siskind D, Baingana F, Kim J.

J Ment Health Policy Econ. 2008 Sep;11(3):127-33.

PMID:
18806302
19.
20.

Clozapine for refractory schizophrenia: the Illinois experience.

Buckman RW, Malan RD.

J Clin Psychiatry. 1999;60 Suppl 1:18-22; discussion 28-30.

Supplemental Content

Support Center